ahlam1399
06-16-2015, 02:24 AM
UPDATE 1-Avalanche eye therapy meets safety goal; vision improvement modest
June 15 (Reuters) - Avalanche Biotech**logies Inc's experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/474361ae/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=DREJ9Vf1UTE:97SUJ7ZgPFk:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=DREJ9Vf1UTE:97SUJ7ZgPFk:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=DREJ9Vf1UTE:97SUJ7ZgPFk:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=DREJ9Vf1UTE:97SUJ7ZgPFk:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=DREJ9Vf1UTE:97SUJ7ZgPFk:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/DREJ9Vf1UTE
June 15 (Reuters) - Avalanche Biotech**logies Inc's experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/474361ae/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=DREJ9Vf1UTE:97SUJ7ZgPFk:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=DREJ9Vf1UTE:97SUJ7ZgPFk:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=DREJ9Vf1UTE:97SUJ7ZgPFk:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=DREJ9Vf1UTE:97SUJ7ZgPFk:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=DREJ9Vf1UTE:97SUJ7ZgPFk:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/DREJ9Vf1UTE